Definite diagnosis is based on endomyocardial biopsy and treatment of cardiac amyloidosis is a challenge. Heart transplantation, although controversial, has demonstrated survival benefit.

The prognosis of patients with cardiac amyloidosis is affected by their cardiac condition, the extracardiac involvement and the modality of treatment of the underlying disease. Another predictor ...

The FDA has approved BridgeBio’s acoramidis (Attruby), a transthyretin (TTR) stabilizer, for cardiac amyloidosis (ATTR-CM). It is the second drug to be approved for this heart disease ...

The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

The drugs attack so-called amyloid plaques in the brain. But how can we reliably and cost effectively diagnose the presence of amyloid plaques in patients who show up at memory clinics with slight ...

The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...

BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and Drug Administration approved Attruby or acoramidis, an ...

There is a simple discount patient access scheme for eplontersen. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact Market.AccessUK ...

Diagnosis of hereditary amyloid transthyretin (hATTR) amyloidosis with cardiomyopathy is frequently delayed, in large part because of symptom overlap with other cardiovascular diseases and limited ...

Keywords: Hypertrophic Cardiomyopathy (HCM), Cardiac Amyloidosis, Myocardial Thickening, Molecular Mechanisms, Genetic Mutations, Advanced Imaging Techniques, Biomarkers, Interventional Cardiology ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...